Peter Youssef

5.0k total citations
87 papers, 3.0k citations indexed

About

Peter Youssef is a scholar working on Rheumatology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peter Youssef has authored 87 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Rheumatology, 26 papers in Pathology and Forensic Medicine and 23 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peter Youssef's work include Rheumatoid Arthritis Research and Therapies (36 papers), Systemic Sclerosis and Related Diseases (23 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (15 papers). Peter Youssef is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (36 papers), Systemic Sclerosis and Related Diseases (23 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (15 papers). Peter Youssef collaborates with scholars based in Australia, United Kingdom and United States. Peter Youssef's co-authors include Malcolm Smith, Angela Parker, Michael Coleman, P J Roberts-Thomson, Michael Ahern, Barry Bresnihan, Oliver FitzGerald, Carolyn L. Geczy, Joanne Sahhar and J V Bertouch and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Immunology and Annals of the Rheumatic Diseases.

In The Last Decade

Peter Youssef

86 papers receiving 2.9k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Peter Youssef	1.3k	817	739	719	613	87	3.0k
Jason Jungsik Song	921 0.7×	722 0.9×	695 0.9×	199 0.3×	468 0.8×	215	2.7k
Philippe Guilpain	885 0.7×	1.4k 1.7×	748 1.0×	962 1.3×	814 1.3×	126	3.4k
Patrícia Carreira	732 0.6×	630 0.8×	390 0.5×	1.2k 1.6×	822 1.3×	104	2.6k
Shin‐ya Kawashiri	1.3k 1.0×	375 0.5×	642 0.9×	269 0.4×	745 1.2×	223	3.0k
Gurtej S. Cheema	1.3k 1.1×	241 0.3×	351 0.5×	489 0.7×	1.2k 1.9×	26	2.9k
Tomoki Origuchi	1.9k 1.5×	468 0.6×	995 1.3×	305 0.4×	1.2k 1.9×	238	4.2k
Alfiya Distler	413 0.3×	622 0.8×	1.3k 1.7×	1.0k 1.4×	549 0.9×	55	2.9k
P. C. Limburg	1.3k 1.0×	1.0k 1.2×	543 0.7×	213 0.3×	1.3k 2.1×	52	3.6k
J. W. Cohen Tervaert	1.1k 0.9×	2.6k 3.2×	528 0.7×	355 0.5×	1.3k 2.1×	77	3.8k
Kunihiro Ichinose	1.3k 1.0×	347 0.4×	773 1.0×	218 0.3×	1.2k 1.9×	188	3.1k

Countries citing papers authored by Peter Youssef

Since Specialization

Citations

This map shows the geographic impact of Peter Youssef's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Youssef with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Youssef more than expected).

Fields of papers citing papers by Peter Youssef

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Youssef. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Youssef. The network helps show where Peter Youssef may publish in the future.

Co-authorship network of co-authors of Peter Youssef

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Youssef. A scholar is included among the top collaborators of Peter Youssef based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Youssef. Peter Youssef is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Youssef, Peter, Joanna Leadbetter, Belinda Butcher, et al.. (2025). Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis. Rheumatology and Therapy. 12(1). 173–202. 3 indexed citations

Parker, Matthew, Adelle S. Jee, Dylan Hansen, et al.. (2024). Multiple serum biomarkers associate with mortality and interstitial lung disease progression in systemic sclerosis. Lara D. Veeken. 63(11). 2981–2988. 5 indexed citations

Littlejohn, Geoffrey, Joanna Leadbetter, Belinda Butcher, et al.. (2024). Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia. Clinical Rheumatology. 43(5). 1579–1589. 2 indexed citations

Littlejohn, Geoffrey, Tamás Treuer, Kathryn Gibson, et al.. (2023). Real-world utilisation and switching between Janus kinase inhibitors in Australian patients with rheumatoid arthritis in the OPAL dataset. Clinical and Experimental Rheumatology. 42(9). 1763–1772. 2 indexed citations

Deakin, Claire T., Geoffrey Littlejohn, Hedley Griffiths, et al.. (2023). Comparative effectiveness of etanercept originator and biosimilar for treating rheumatoid arthritis: implications for cost‐savings. Internal Medicine Journal. 54(5). 795–801. 1 indexed citations

Littlejohn, Geoffrey, Tamás Treuer, Kathryn Gibson, et al.. (2023). Comparative Effectiveness of First‐Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data Set. ACR Open Rheumatology. 5(7). 345–353. 2 indexed citations

Sammel, Anthony M., Edward Hsiao, Geoffrey Schembri, et al.. (2020). Cranial and large vessel activity on positron emission tomography scan at diagnosis and 6 months in giant cell arteritis. International Journal of Rheumatic Diseases. 23(4). 582–588. 28 indexed citations

Sammel, Anthony M., Edward Hsiao, Geoffrey Schembri, et al.. (2019). Diagnostic Accuracy of Positron Emission Tomography/Computed Tomography of the Head, Neck, and Chest for Giant Cell Arteritis: A Prospective, Double‐Blind, Cross‐Sectional Study. Arthritis & Rheumatology. 71(8). 1319–1328. 91 indexed citations

Owen, Claire, Gene‐Siew Ngian, O. Moore, et al.. (2017). Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.. PubMed. 34 Suppl 100(5). 170–176. 28 indexed citations

10.

Thakkar, Vivek, Wendy Stevens, David L. Prior, et al.. (2017). The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study.. PubMed. 34 Suppl 100(5). 129–136. 16 indexed citations

11.

Hao, Yue, Wendy Stevens, Kathleen Morrisroe, et al.. (2014). A comparison of the predictive accuracy of three screening models (DETECT v.ESC/ERS v. ASIG) for pulmonary arterial hypertension in systemic sclerosis. Internal Medicine Journal. 44(11). 23–23. 1 indexed citations

12.

Nicholls, Dave, Jane Zochling, David A. Mathers, et al.. (2013). A retrospective chart review of the use of rituximab for the treatment of rheumatoid arthritis in A ustralian rheumatology practice. International Journal of Rheumatic Diseases. 17(7). 755–761. 5 indexed citations

13.

Thakkar, Vivek, Wendy Stevens, David L. Prior, et al.. (2013). Asymmetric dimethylarginine levels in the early detection of systemic sclerosis-related pulmonary arterial hypertension. Adelaide Research & Scholarship (AR&S) (University of Adelaide). 1 indexed citations

14.

Nicholls, Dave, Jane Zochling, D A Mathers, et al.. (2012). A retrospective chart review of mabthera (rituximab) for rheumatoid arthritis (Ra) in Australian rheumatology practice. Internal Medicine Journal. 42. 3–3. 1 indexed citations

15.

Nash, Peter, S M Hall, Graeme Jones, et al.. (2012). Tofacitinib (cp-690,550), an oral Janus Kinase Inhibitor: Pooled phase 3 analysis in an Australian Rheumatoid Arthritis Study Population. Internal Medicine Journal. 42. 14–14. 6 indexed citations

16.

Byron, J., Jane Zochling, Janet Roddy, et al.. (2011). MORTALITY AND CAUSES OF DEATH IN AN AUSTRALIAN SYSTEMIC SCLEROSIS COHORT. Internal Medicine Journal. 41. 12–12. 1 indexed citations

17.

Nash, Peter, et al.. (2011). SAFETY AND TOLERABILITY OF TOCILIZUMAB IN LONG-TERM EXTENSION STUDIES OF RHEUMATOID ARTHRITIS. Internal Medicine Journal. 41. 17–17. 1 indexed citations

18.

Stevens, Wendy, Mandana Nikpour, Julie K. Byron, et al.. (2011). FREQUENCY, CLINICAL CHARACTERISTICS AND RISK FACTORS FOR DIGITAL ULCERS IN SYSTEMIC SCLEROSIS. Internal Medicine Journal. 41. 13–13. 3 indexed citations

19.

Wong, Peter K. K., et al.. (2001). Effects of pulse methylprednisolone on macrophage chemotactic protein-1 and macrophage inflammatory protein-1alpha in rheumatoid synovium.. PubMed. 28(12). 2634–6. 13 indexed citations

20.

Youssef, Peter, Johannes Roth, Michael Frosch, et al.. (1999). Expression of myeloid related proteins (MRP) 8 and 14 and the MRP8/14 heterodimer in rheumatoid arthritis synovial membrane.. PubMed. 26(12). 2523–8. 121 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact